U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C13H18O2.C7H17NO5
Molecular Weight 401.4944
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IBUPROFEN MEGLUMINE

SMILES

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(C)CC1=CC=C(C=C1)C(C)C(O)=O

InChI

InChIKey=VXVMMZWKWPUJIT-WZTVWXICSA-N
InChI=1S/C13H18O2.C7H17NO5/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15;1-8-2-4(10)6(12)7(13)5(11)3-9/h4-7,9-10H,8H2,1-3H3,(H,14,15);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

HIDE SMILES / InChI

Molecular Formula C13H18O2
Molecular Weight 206.2808
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula C7H17NO5
Molecular Weight 195.2136
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20718179

Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are thought to act through inhibition of prostaglandin synthesis. It’s used temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps and temporarily reduces fever. The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
27.9 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBUPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
103 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBUPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.2 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBUPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
IBUPROFEN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Other AEs: Cardiovascular collapse, Acidosis...
Other AEs:
Cardiovascular collapse (grade 5, 1 patient)
Acidosis (grade 5, 1 patient)
Hypothermia (grade 5, 1 patient)
Sources:
90 g single, oral
Overdose
Dose: 90 g
Route: oral
Route: single
Dose: 90 g
Sources:
unknown, 19 years
Health Status: unknown
Age Group: 19 years
Sex: M
Sources:
Other AEs: Polyuria, Acidosis...
Other AEs:
Polyuria (1 patient)
Acidosis (1 patient)
Sources:
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Other AEs: Acute respiratory distress syndrome, Tachypnea...
Other AEs:
Acute respiratory distress syndrome (serious, 1 patient)
Tachypnea (serious, 1 patient)
Septic shock (serious, 1 patient)
Breathlessness (serious, 1 patient)
Septicemia (serious, 1 patient)
Sources:
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources: Page: p.87
unhealthy, 42 years (range: 17-73 years)
n = 195
Health Status: unhealthy
Age Group: 42 years (range: 17-73 years)
Sex: M+F
Population Size: 195
Sources: Page: p.87
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (2%)
Headache (1 patient)
Sources: Page: p.87
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources: Page: p.87
unhealthy, 44 years (range: 20-69 years)
n = 304
Health Status: unhealthy
Age Group: 44 years (range: 20-69 years)
Sex: M+F
Population Size: 304
Sources: Page: p.87
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (2 patients)
Sources: Page: p.87
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Co-administed with::
divalproex sodium
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Other AEs: Cardiovascular collapse...
Other AEs:
Cardiovascular collapse (grade 5, 1 patient)
Sources:
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Other AEs: Acidosis, Hypothermia...
Other AEs:
Acidosis (grade 5, 1 patient)
Hypothermia (grade 5, 1 patient)
Sources:
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Pain
Age Group: adult
Sources:
Other AEs: Myocardial infarction, Stroke...
Other AEs:
Myocardial infarction (serious|grade 5)
Stroke (serious|grade 5)
Sources:
400 mg 6 times / day multiple, oral
Recommended
Dose: 400 mg, 6 times / day
Route: oral
Route: multiple
Dose: 400 mg, 6 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
Other AEs: Myocardial infarction, Stroke...
Other AEs:
Myocardial infarction (serious|grade 5)
Stroke (serious|grade 5)
Sources:
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Other AEs: Depression, Insomnia...
Other AEs:
Depression (below serious, 1 patient)
Insomnia (below serious, 1 patient)
Oropharyngeal pain (below serious, 1 patient)
Sinus congestion (below serious, 1 patient)
Sources:
97.5 mg 4 times / day multiple, oral
Dose: 97.5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 97.5 mg, 4 times / day
Sources:
unhealthy
n = 112
Health Status: unhealthy
Condition: Dental Pain
Population Size: 112
Sources:
Other AEs: Facial swelling...
Other AEs:
Facial swelling (below serious, 8 patients)
Sources:
10 mg/kg single, oral
Dose: 10 mg/kg
Route: oral
Route: single
Dose: 10 mg/kg
Sources:
unhealthy
n = 29
Health Status: unhealthy
Condition: Post-ERCP Pancreatitis
Population Size: 29
Sources:
Other AEs: Bleeding, Perforation...
Other AEs:
Bleeding (below serious, 2 patients)
Perforation (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Acidosis grade 5, 1 patient
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Cardiovascular collapse grade 5, 1 patient
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Hypothermia grade 5, 1 patient
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Acidosis 1 patient
90 g single, oral
Overdose
Dose: 90 g
Route: oral
Route: single
Dose: 90 g
Sources:
unknown, 19 years
Health Status: unknown
Age Group: 19 years
Sex: M
Sources:
Polyuria 1 patient
90 g single, oral
Overdose
Dose: 90 g
Route: oral
Route: single
Dose: 90 g
Sources:
unknown, 19 years
Health Status: unknown
Age Group: 19 years
Sex: M
Sources:
Acute respiratory distress syndrome serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Breathlessness serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Septic shock serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Septicemia serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Tachypnea serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Headache 1 patient
Disc. AE
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources: Page: p.87
unhealthy, 42 years (range: 17-73 years)
n = 195
Health Status: unhealthy
Age Group: 42 years (range: 17-73 years)
Sex: M+F
Population Size: 195
Sources: Page: p.87
Dizziness 2%
Disc. AE
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources: Page: p.87
unhealthy, 42 years (range: 17-73 years)
n = 195
Health Status: unhealthy
Age Group: 42 years (range: 17-73 years)
Sex: M+F
Population Size: 195
Sources: Page: p.87
Headache 2 patients
Disc. AE
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources: Page: p.87
unhealthy, 44 years (range: 20-69 years)
n = 304
Health Status: unhealthy
Age Group: 44 years (range: 20-69 years)
Sex: M+F
Population Size: 304
Sources: Page: p.87
Cardiovascular collapse grade 5, 1 patient
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Co-administed with::
divalproex sodium
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Acidosis grade 5, 1 patient
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Hypothermia grade 5, 1 patient
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Myocardial infarction serious|grade 5
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Pain
Age Group: adult
Sources:
Stroke serious|grade 5
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Pain
Age Group: adult
Sources:
Myocardial infarction serious|grade 5
400 mg 6 times / day multiple, oral
Recommended
Dose: 400 mg, 6 times / day
Route: oral
Route: multiple
Dose: 400 mg, 6 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
Stroke serious|grade 5
400 mg 6 times / day multiple, oral
Recommended
Dose: 400 mg, 6 times / day
Route: oral
Route: multiple
Dose: 400 mg, 6 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
Depression below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Insomnia below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Oropharyngeal pain below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Sinus congestion below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Facial swelling below serious, 8 patients
97.5 mg 4 times / day multiple, oral
Dose: 97.5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 97.5 mg, 4 times / day
Sources:
unhealthy
n = 112
Health Status: unhealthy
Condition: Dental Pain
Population Size: 112
Sources:
Perforation below serious, 1 patient
10 mg/kg single, oral
Dose: 10 mg/kg
Route: oral
Route: single
Dose: 10 mg/kg
Sources:
unhealthy
n = 29
Health Status: unhealthy
Condition: Post-ERCP Pancreatitis
Population Size: 29
Sources:
Bleeding below serious, 2 patients
10 mg/kg single, oral
Dose: 10 mg/kg
Route: oral
Route: single
Dose: 10 mg/kg
Sources:
unhealthy
n = 29
Health Status: unhealthy
Condition: Post-ERCP Pancreatitis
Population Size: 29
Sources:
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
minor
minor
minor
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Letter: Aspirin sensitivity: other drugs.
1975 Feb
[Renal tubular acidosis with severe hypokalemic tetraparesis after ibuprofen intake].
1999 Apr 23
Recurrence of ibuprofen-induced aseptic meningitis in an otherwise healthy patient.
1999 Feb
Topical non-steroidal drugs are systemically absorbed and may cause renal disease.
1999 Jan
Spinal antinociceptive effect of epidural nonsteroidal antiinflammatory drugs on nitric oxide-induced hyperalgesia in rats.
1999 Jul
Low-dose diclofenac, naproxen, and ibuprofen cohort study.
1999 Jul
Induction of stromelysin gene expression by tumor necrosis factor alpha is inhibited by dexamethasone, salicylate, and N-acetylcysteine in synovial fibroblasts.
1999 Jun
Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes.
1999 May
Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells.
1999 May 21
Interstitial nephritis in children with Crohn's disease.
2000 Apr
The effect of spinal ibuprofen on opioid withdrawal in the rat.
2000 Aug
Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro.
2000 Aug 11
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta.
2000 Feb 11
Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus.
2000 Jan
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells.
2000 Nov 17
Group B Streptococci and inducible nitric oxide synthase: modulation by nuclear factor kappa B and ibuprofen.
2001 Apr
In vitro effect of different non-steroidal anti-inflammatory drugs on human polymorphonuclear leukocyte activity measured by luminol-dependent chemiluminescence of the whole blood.
2001 Apr
Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
2001 Apr
Nonsurgical female sterilization: comparison of intrauterine application of quinacrine alone or in combination with ibuprofen.
2001 Apr
Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.
2001 Apr 15
Determination of nonsteroidal anti-inflammatory drugs in biological fluids by automatic on-line integration of solid-phase extraction and capillary electrophoresis.
2001 Feb
Ibuprofen affects pro- and anti-inflammatory cytokine production by mononuclear cells of preterm newborns.
2001 Feb
[Topical administration is better than oral administration].
2001 Feb 1
The role of acetaminophen in the management of patients with osteoarthritis.
2001 Feb 19
Functional evidence for an inward rectifier potassium current in rat renal afferent arterioles.
2001 Feb 2
Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea.
2001 Feb 20
Determination of drug residues in water by the combination of liquid chromatography or capillary electrophoresis with electrospray mass spectrometry.
2001 Feb 23
Activity profile of glycolamide ester prodrugs of ibuprofen.
2001 Jan
Analgesia for colposcopy: double-masked, randomized comparison of ibuprofen and benzocaine gel.
2001 Jan
Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
2001 Jan
Ibuprofen for closure of patent ductus arteriosus.
2001 Jan
Ibuprofen as a chemesthetic stimulus: evidence of a novel mechanism of throat irritation.
2001 Jan
Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs.
2001 Jan 19
Penetration enhancement of ibuprofen from supersaturated solutions through human skin.
2001 Jan 5
Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms.
2001 Mar
Expression of rat liver long-chain acyl-CoA synthetase and characterization of its role in the metabolism of R-ibuprofen and other fatty acid-like xenobiotics.
2001 Mar 15
Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at the low-ng/l level in surface and waste water.
2001 Mar 16
Patents

Sample Use Guides

adults: take 1 tablet every 4 to 6 hours while symptoms persist. If pain or fever does not respond to 1 tablet, 2 tablets may be used; do not exceed 6 tablets in 24 hours. Children under 12 years: ask a doctor.
Route of Administration: Oral
Ibuprofen, in a 400-μM concentration, decreased the expression of Hsp70 by 23% in comparison with untreated cells, whereas other NSAID had no effect. Ibuprofen also decreased the expression of Hsp70 in H358, a human lung adenocarcinoma cell line, in a dose-dependent manner (from 0-400 uM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:01:29 GMT 2023
Edited
by admin
on Sat Dec 16 10:01:29 GMT 2023
Record UNII
56SFW97YYQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IBUPROFEN MEGLUMINE
WHO-DD  
Common Name English
Ibuprofen meglumine [WHO-DD]
Common Name English
(2R,3R,4R,5S)-6-(METHYLAMINO)HEXANE-1,2,3,4,5-PENTOL, 2-(4-(2-METHYLPROPYL)PHENYL)PROPANOIC ACID
Systematic Name English
IBUPROFEN METHYLGLUCAMINE SALT
Common Name English
BENZENEACETIC ACID, .ALPHA.-METHYL-4-(2-METHYLPROPYL)-, COMPD. WITH 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL (1:1)
Systematic Name English
D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, .ALPHA.-METHYL-4-(2-METHYLPROPYL)BENZENEACETATE (SALT)
Systematic Name English
D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, .ALPHA.-METHYL-4-(2-METHYLPROPYL)BENZENEACETATE (1:1)
Systematic Name English
ARTRENE
Brand Name English
2-(4-ISOBUTYLPHENYL)PROPANOIC ACID-1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
9930909
Created by admin on Sat Dec 16 10:01:29 GMT 2023 , Edited by admin on Sat Dec 16 10:01:29 GMT 2023
PRIMARY
EVMPD
SUB02627MIG
Created by admin on Sat Dec 16 10:01:29 GMT 2023 , Edited by admin on Sat Dec 16 10:01:29 GMT 2023
PRIMARY
FDA UNII
56SFW97YYQ
Created by admin on Sat Dec 16 10:01:29 GMT 2023 , Edited by admin on Sat Dec 16 10:01:29 GMT 2023
PRIMARY
SMS_ID
100000086960
Created by admin on Sat Dec 16 10:01:29 GMT 2023 , Edited by admin on Sat Dec 16 10:01:29 GMT 2023
PRIMARY
CAS
135861-34-6
Created by admin on Sat Dec 16 10:01:29 GMT 2023 , Edited by admin on Sat Dec 16 10:01:29 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY